Delving into the Latest Updates on ALLO-ASC-DFU(Anterogen) with Synapse

Overview

Basic Info

Drug Type

Stem cell therapy

Synonyms

ALLO-ASC-SHEET

Target-

Mechanism

Cell replacements

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [4]

Active Indication

Diabetic foot ulcerEpidermolysis Bullosa Dystrophica

Inactive Indication

BurnsGlomerulonephritis, IGA

Originator Organization

Anterogen Co., Ltd.

Active Organization

Anterogen Co., Ltd.

Inactive Organization

Ishin Pharmaceutical Co. Ltd.

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

After confirming eligibility, a single subject with four selected target lesions will receive both ALLO-ASC-SHEET and Vehicle control, three target lesions for ALLO-ASC-SHEET and the other target for Vehicle control, and which lesion to apply which IP treatment will be determined randomly at the time of enrollment using pre-designed block randomization scheme.

Start Date01 May 2023

Sponsor / Collaborator

Anterogen Co., Ltd.

NCT06141811 / RecruitingNot Applicable

A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial

This is a follow-up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial (ALLO-ASC-DFU-302) for 24 months

Start Date25 Apr 2023

Sponsor / Collaborator

Anterogen Co., Ltd.

NCT04497805 / RecruitingPhase 2

A Phase 2 Clinical Study to Evaluate The Efficacy and Safety of ALLO-ASC-SHEET in the Subjects With Diabetic Wagner Grade II Foot Ulcers

This is a phase 2 double-blind clinical study to evaluate the efficacy and Safety of ALLO-ASC-SHEET in subjects with Diabetic Wagner Grade II Foot Ulcers, compared to placebo therapy.

Start Date08 Sep 2020

Sponsor / Collaborator

Anterogen Co., Ltd.

100 Clinical Results associated with ALLO-ASC-DFU(Anterogen)

Login to view more data

100 Translational Medicine associated with ALLO-ASC-DFU(Anterogen)

Login to view more data

100 Patents (Medical) associated with ALLO-ASC-DFU(Anterogen)

Login to view more data

100 Deals associated with ALLO-ASC-DFU(Anterogen)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic foot ulcer	Phase 3	KR	Anterogen Co., Ltd.	27 Jun 2018
Epidermolysis Bullosa Dystrophica	Phase 2	KR	Anterogen Co., Ltd.	08 Dec 2015
Burns	Phase 1	KR	Anterogen Co., Ltd.	23 Dec 2015
Glomerulonephritis, IGA	Phase 1	KR	Anterogen Co., Ltd.	28 Jun 2013
Epidermolysis Bullosa	Discovery	JP	Ishin Pharmaceutical Co. Ltd.	01 Mar 2021